Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode.
Brainstorm Cell Therapeutics Inc. (BCLI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 690,666 | $870,239 | 0.01% | |
| 2. | Ikarian Capital Neil Shahrestani | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.43 | 1,836 | $6,292.34 | 80,960 | 2024-10-01 | Filing | |
| $0.23 | 22,000 | $5,016.00 | 1,186,865 | 2024-09-30 | Filing | |
| $0.52 | 15,000 | $7,774.50 | 1,164,865 | 2024-05-28 | Filing | |
| $0.64 | 25,000 | $16,000.00 | 1,149,865 | 2024-05-22 | Filing | |
| $0.58 | 25,000 | $14,475.00 | 1,124,865 | 2024-05-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.35 | 63,000 | $22,068.90 | 0 | 2024-07-19 | Filing | |
| $13.47 | 7,823 | $105,350.78 | 67,053 | 2020-07-16 | Filing | |
| $13.12 | 18,430 | $241,714.98 | 74,876 | 2020-07-15 | Filing | |
| $13.52 | 40,000 | $540,952.00 | 93,306 | 2020-07-13 | Filing | |
| $13.35 | 2,000 | $26,700.00 | 133,306 | 2020-07-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 266 | $298 | 0% | |
| 2. | 157,009 | $0 | 0% |
News See All
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript March 31, 2025Brainstorm Cell Therapeutics Inc. reports earnings inline with expectations.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Brainstorm Cell Therapeutics Second Quarter 2024 Conference Call. At this time, participants are in a listen-only mode.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the BrainStorm Cell Therapeutics Third Quarter 2023 Earnings Call. At this time, participants are in a listen-only mode. As a reminder, this call is being recorded.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Brainstorm Cell Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Brainstorm Cell Therapeutics First Quarter 2023 Earnings Call. At this time, participants are in a listen-only mode. As a reminder this call is being recorded.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to the Brainstorm Cell Therapeutics Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
Is Brainstorm Cell Therapeutics Inc. (BCLI) A Good Stock To Buy?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.
Hedge Funds Aren't Crazy About Brainstorm Cell Therapeutics Inc. (BCLI) Anymore
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Hedge Fund and Insider Trading News: Michael Tiedemann, Steve Cohen, BlueBay Asset Management, Brainstorm Cell Therapeutics Inc (BCLI), ADDvantage Technologies Group, Inc. (AEY), and More
THAT WORRY ACCOMPANIES WEALTH may seem paradoxical, but Michael Tiedemann says his firm’s 400-plus client households almost invariably fret about their heirs.
Billionaire Hedge Funds
